Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has predictably returned. To cope, yes, we are firing up the trusty coffee kettle and brewing cups of stimulation. Our choice today is a regular roast sprinkled with a dash of cinnamon. Try it some time. Meanwhile, here are a few tidbits to get you moving along your own journey. We hope all goes well today and you conquer the world, such as it is. …

A real-world data study in Israel found the coronavirus variant discovered in South Africa can “break through” the Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) to an extent, though its prevalence in the country is low and the research was not peer reviewed, Reuters writes. The study compared almost 400 people who tested positive 14 days or more after receiving one or two doses against the same number of unvaccinated patients. Among positive patients given two doses, the variant’s prevalence rate was eight times higher than among infected unvaccinated people — 5.4% versus 0.7%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]